Gujarat Themis Biosyn Limited has expanded its international footprint by incorporating a wholly owned subsidiary, Themis Biosyn Ireland Private Limited, in Ireland on May 29, 2026. The strategic move marks the company's entry into the European market, with the new entity operating within the pharmaceutical industry. Gujarat Themis Biosyn holds 100% of the shareholding in the subsidiary, ensuring complete control over its operations.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary was registered with a share capital of 1,00,000 Euro. The Business registration extract for the new entity was received on the same date as its incorporation.

Details regarding the new subsidiary were provided in an annexure to the regulatory filing. The document clarified that the incorporation does not constitute a related party transaction, nor does it involve any interest from the promoter, promoter group, or other group companies. Consequently, specific details regarding acquisition costs, consideration, and regulatory approvals were noted as not applicable.

Subsidiary Details

The following table outlines the key particulars of the newly incorporated entity:

The filing was signed by Dinesh S. Patel, Chairman & Director of Gujarat Themis Biosyn Limited. The information has been submitted to BSE Limited and the National Stock Exchange of India Limited for public dissemination.

Gujarat Themis Biosyn Limited reported a net profit of ₹4,668.15 lakh for the financial year ended March 31, 2026, compared to ₹4,877.17 lakh in the previous year. Total income for the year rose to ₹16,825.09 lakh from ₹15,323.23 lakh in FY25. The Board of Directors, meeting on May 25, 2026, approved the audited financial results and recommended a final dividend of Re. 0.67 per equity share for the fiscal year.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹1,089.12 lakh. Income from operations for the quarter stood at ₹4,423.30 lakh, while total income was ₹4,515.41 lakh. For the full year, income from operations increased to ₹16,582.28 lakh from ₹15,079.99 lakh in the previous year.

Dividend Recommendation

The Board has recommended a final dividend of Re. 0.67 per equity share, representing 67% of the face value of Re. 1 each. The total dividend payout aggregates to ₹7,30,06,728 and is subject to the approval of shareholders at the ensuing Annual General Meeting.

Corporate Developments

The Board approved the appointment of M/s. Raja Dutta & Co., Cost Accountants, as the Cost Auditor for the financial year 2026-27. Additionally, the board approved a proposal for a preferential issue of equity shares to Non-Promoters. A Preferential Issue Committee has been constituted to finalize the terms and conditions of the proposed issue, subject to necessary regulatory and shareholder approvals.